EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results: Revenue of $90.4 million GAAP loss of $13.2 million, or $(0.48) per share Non-GAAP loss of $2.4 million, or $(0.09) per share Adjusted EBITDA loss of $7.5 million No
